Compare · BHSE vs SGEN
BHSE vs SGEN
Side-by-side comparison of Bull Horn Holdings Corp. (BHSE) and Seagen Inc. (SGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BHSE and SGEN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- SGEN is the larger of the two at $23.34B, about 248.7x BHSE ($93.8M).
- SGEN has more recent analyst coverage (25 ratings vs 0 for BHSE).
- Company
- Bull Horn Holdings Corp.
- Seagen Inc.
- Price
- $12.50+50.42%
- $228.86-0.01%
- Market cap
- $93.8M
- $23.34B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2001
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 25
Bull Horn Holdings Corp.
Bull Horn Holdings Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the sports, entertainment, and brands sectors. The company was incorporated in 2018 and is based in Miami Beach, Florida.
Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Latest BHSE
- SEC Form SC 13G filed by Bull Horn Holdings Corp.
- SEC Form 424B3 filed by Bull Horn Holdings Corp.
- SEC Form 424B3 filed by Bull Horn Holdings Corp.
- Bull Horn Holdings Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events
- Cogley Brian bought $3,350 worth of shares (5,000 units at $0.67), increasing direct ownership by 20% to 30,000 units (SEC Form 4)
- New insider Cogley Brian claimed ownership of 30,000 shares (SEC Form 3)
- Desilva Tara bought $1,305 worth of shares (2,266 units at $0.58), increasing direct ownership by 8% to 32,266 units (SEC Form 4)
- Yerace Daniel Alexander bought $7,486 worth of shares (10,850 units at $0.69), increasing direct ownership by 1% to 1,071,455 units (SEC Form 4)
- Salkind Gene bought $8,004 worth of shares (11,600 units at $0.69), increasing direct ownership by 4% to 284,056 units (SEC Form 4)
- Mehalick David bought $16,747 worth of shares (25,054 units at $0.67), increasing direct ownership by 0.91% to 2,782,615 units (SEC Form 4)
Latest SGEN
- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Alltrna Announces Updates to Its Board of Directors
- Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
- How To Earn $500 A Month From Pfizer Stock
- Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
- SEC Form 15-12G filed by Seagen Inc.
- Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- SEC Form SC 13D/A filed by Seagen Inc. (Amendment)
- Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)